Associated Papers
Predicted deleterious variants in the human genome relevant to gene therapy with adeno-associated virus vectors.
Rostami MR et al.
Molecular Therapy. Methods & Clinical Development, 2023
38089635 (PubMed )
Supplement: mmc2.xlsx › Supplemental_Table_III
In Silico-Based Structural Evaluation to Categorize the Pathogenicity of Mutations Identified in the RAD Class of Proteins.
Anwaar A et al.
Acs Omega, 2023
TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.
Lesueur F et al.
Cancers, 2021
34359559 (PubMed )
Supplement: cancers-13-03659-s001.zip › cancers-1273124-supplementary.pdf
BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
Suszynska M et al.
Journal of Ovarian Research, 2020
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM et al.
Oncology, 2016
RAD50 gene mutations are not likely a risk factor for breast cancer in Poland.
Mosor M et al.
Breast Cancer Research and Treatment, 2010
Evaluation of RAD50 in familial breast cancer predisposition.
Tommiska J et al.
International Journal of Cancer, 2006
Select a paper to view details